Sam Smith on the Association Between Adherence and Menopausal Symptoms

Patients with metastatic breast cancer who received ribociclib plus fulvestrant achieved a median progression-free survival of 18.1 months vs 5.29 months with placebo/fulvestrant.

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

A telephone-based weight loss program proved to be efficacious in overweight or obese women with breast cancer and may lead to improved disease outcomes in the long run.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Combined treatment with capivasertib plus fulvestrant yielded a 5.5-month median progression-free survival for patients with HR+ advanced breast cancer.

Patients with early-stage HER2-positive breast cancer experienced a high rate of pathologic complete response with combined preoperative treatment with atezolizumab, epirubicin, trastuzumab, and pertuzumab.